Stifel Nicolaus Thinks Urogen Pharma Ltd’s Stock is Going to Recover

By Ryan Adsit

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma Ltd (URGNResearch Report), with a price target of $63. The company’s shares opened today at $39.66, close to its 52-week low of $36.95.

Archila said:

“We are reiterating our Buy rating on URGN shares post its 4Q18 financial report and business update. We remain bullish on its lead program, MitoGel (UGN-101) which is being developed as a non-surgical treatment option for patients with upper tract urothelial carcinoma (UTUC), a niche, but high unmet need patient population. We continue to await the completion of URGN’s OLYMPUS Phase 3 study for MitoGel in UTUC, which we previously estimated could finish in the August 2019 timeframe in order for ~75% of patients achieving a CR to reach the 6-month time point. While there was not much new in terms of an update on last week’s conference call, we believe the company remains well positioned to execute on its plan to complete its rolling NDA submission in the 2H19 setting up a 1H20 launch along with the ability to leverage its RTGel platform for business development opportunities.”

According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 39.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Selecta Biosciences.

Urogen Pharma Ltd has an analyst consensus of Strong Buy, with a price target consensus of $66.25, implying a 67.0% upside from current levels. In a report issued on February 28, Oppenheimer also assigned a Buy rating to the stock with a $70 price target.

See today’s analyst top recommended stocks >>

Based on Urogen Pharma Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $23.72 million. In comparison, last year the company had a GAAP net loss of $10.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.